Despite its promise, effective responses to adoptive immunotherapy have been documented against only a restricted number of tumor types and this approach to cancer therapy has been further restricted by toxicity associated with the need for exogenous administration of interleukin-2. This evidence concerns the gene IL2 and neoplasm.